Erdafitinib Continues to Show Efficacy in Urothelial Carcinoma
The pan-FGFR tyrosine kinase inhibitor erdafitinib (Balversa) was active and safe in patients with locally advanced or metastatic urothelial carcinoma, according to long-term follow-up of a phase II study. At a median follow-up of 24 months, the investigator-assessed objective response rate (ORR) was 40% among 101 patients with prespecified FGFR alterations treated with erdafitinib, reported […]